Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk Says More To Victoza Outcomes Benefit Than A GLP-1 Class Effect

Executive Summary

Novo Nordisk's ESC satellite symposium on heels of FDA approval of CV event prevention claim for Victoza highlights differences compared to Sanofi's competing Lyxumia, which failed an outcomes study.

You may also be interested in...



Novo Nordisk Fortifies Cardio-Renal Efforts With Corvidia Buy

Novo Nordisk is paying $725m to acquire the VC-backed US biotech, Corvidia Therapeutics and its promising Phase II candidate, ziltivekimab, for chronic kidney disease, but further payments could total more than $2bn.

Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test

The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.

Advantage Novo As Victoza Gets CV Benefit Okay in Europe

Victoza is the only drug in the GLP-1 class in Europe to have a label that includes the prevention of CV events (and only the second antidiabetic after Boehringer Ingelheim/Lilly’s SGLT2 inhibitor Jardiance) which will help slow down market share loss to Lilly's Trulicity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel